XML 49 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition (Tables)
 6 Months Ended
Jun. 27, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
We generated net sales in the following geographic locations(1) (in millions):
 
Three Months Ended
 
Six Months Ended
 
June 27,
2020
 
June 29,
2019
 
June 27,
2020
 
June 29,
2019
U.S.
$
848.7

 
$
768.6

 
$
1,750.3

 
$
1,537.4

Europe(2)
311.8

 
315.8

 
684.4

 
656.7

All other countries(3)
58.6

 
64.6

 
125.4

 
129.4

Total net sales
$
1,219.1

 
$
1,149.0

 
$
2,560.1

 
$
2,323.5


(1) Derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $7.8 million and $11.5 million for the three and six months ended June 27, 2020, respectively, and $6.9 million and $12.1 million for the three and six months ended June 29, 2019, respectively.
(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

Product Category

We re-aligned our product categories in our CSCA and CSCI segments as of December 31, 2019. The re-alignment standardizes our categories and product level detail to provide consistency. This transformative step will optimize the way in which management reports and evaluates our business.

    
The following is a summary of our net sales by category (in millions); the comparative periods reflect the product category re-alignment:
 
Three Months Ended
 
Six Months Ended
 
June 27,
2020
 
June 29,
2019
 
June 27,
2020
 
June 29,
2019
CSCA(1)
 
 
 
 
 
 
 
Upper respiratory
$
116.7

 
$
121.2

 
$
271.3

 
$
254.0

Digestive health
112.1

 
106.3

 
219.0

 
208.6

Pain and sleep-aids
97.7

 
91.3

 
218.1

 
182.6

Nutrition
88.6

 
85.9

 
190.8

 
185.5

Healthy lifestyle
81.5

 
86.1

 
167.3

 
162.1

Oral self-care
63.2

 
—

 
118.5

 
—

Skincare and personal hygiene
42.9

 
45.8

 
89.6

 
91.3

Vitamins, minerals, and supplements
6.4

 
6.2

 
12.8

 
12.5

Animal health
—

 
22.3

 
—

 
41.9

Other CSCA(2)
18.5

 
17.0

 
40.8

 
25.4

Total CSCA
627.6

 
582.1

 
1,328.2

 
1,163.9

CSCI
 
 
 
 
 
 
 
Skincare and personal hygiene
97.6

 
105.7

 
192.3

 
207.6

Upper respiratory
45.5

 
49.9

 
129.6

 
121.8

Healthy lifestyle
40.5

 
48.7

 
84.1

 
96.0

Pain and sleep-aids
40.2

 
39.4

 
87.0

 
79.8

Vitamins, minerals, and supplements
38.5

 
41.1

 
87.0

 
86.9

Oral self-care
20.4

 
1.8

 
43.6

 
3.4

Digestive health
5.1

 
6.8

 
11.1

 
14.0

Other CSCI(3)
33.3

 
34.1

 
69.1

 
68.8

Total CSCI
321.1

 
327.5

 
703.8

 
678.3

RX
270.4

 
239.4

 
528.1

 
481.3

Total net sales
$
1,219.1

 
$
1,149.0

 
$
2,560.1

 
$
2,323.5


(1)    Includes net sales from our OTC contract manufacturing business.
(2)
Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.    
(3)
Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
Contract with Customer Balances
The following table provides information about contract assets from contracts with customers (in millions):
 
Balance Sheet Location
 
June 27,
2020
 
December 31,
2019
Short-term contract assets
Prepaid expenses and other current assets
 
$
22.7

 
$
26.3